SCHEMBL6565726

SCHEMBL6565726

CCCNS(=O)(=O)c1c(Cl)ccc(N)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.46
CA9 Q16790 2/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CXCR2 P25025 2/20 0.41
POLB P06746 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
KMT2A Q03164 3/20 0.36
CYP2C19 P33261 3/20 0.35
ALDH1A1 P00352 3/20 0.35
CYP2C9 P11712 1/20 0.35
TSHR P16473 3/20 0.35
LMNA P02545 3/20 0.35
CYP3A4 P08684 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
THRB P10828 1/20 0.35
NFKB1 P19838 1/20 0.35
HTR2A P28223 1/20 0.35
ADRA1A P35348 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6565765 0.88 VCAM1 (0.41) CXCR2KMT2AALDH1A1CYP2C9TSHR
SCHEMBL6562115 0.87 GSTO1 (0.43) CXCR2L3MBTL1KMT2ACYP2C19ALDH1A1
SCHEMBL6563454 0.85 CXCR2 (0.44) CXCR2L3MBTL1KMT2AALDH1A1TSHR
SCHEMBL6565584 0.85 CXCR2 (0.56) CXCR2POLBL3MBTL1KMT2AALDH1A1
SCHEMBL6564241 0.85 TSHR (0.50) CA12CA9CA2CXCR2POLB
SCHEMBL27552122 0.83 FABP4 (0.42) CA1CA2CXCR2ALDH1A1MEP1B
SCHEMBL6565796 0.82 LMNA (0.40) CA1CA2CXCR2POLBL3MBTL1
SCHEMBL6563387 0.81 CXCR2 (0.43) CXCR2KMT2AALDH1A1TSHRLMNA
SCHEMBL6550689 0.80 CA12 (0.39) CA12CA9CA1CA2CXCR2
SCHEMBL6563384 0.79 GAA (0.46) CA12CA9CA1CA2CXCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1161232-B1 HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-03-24 EP disclosed
US-20030109527-A1 Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-06-12 US disclosed
US-6500863-B1 INTERLEUKIN BINDING INHIBITORS SUCH AS N-(2-HYDROXYL-3-AMINO SULFONYL-4-CHLOROPHENYL)-N'-(2-BROMOPHENYL)UREA, USED FOR PROPHYLAXIS OF CHEMOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION 2002-12-31 US disclosed
EP-1161232-A4 HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2002-09-18 EP disclosed
EP-1161232-A1 HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2001-12-12 EP disclosed
WO-2000035442-A1 HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109527-A1 Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists CXCL8, CCR8, IL18 CA12 4102/4885CA9 3812/4885CA1 4428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.